MK-3475:Phase 3 Randomized, Double-Blind, Placebo-Controlled Trial of Pembrolizumab (MK-3475) Plus Chemotherapy Versus Chemotherapy Plus Placebo for the First-Line Treatment of Persistent, Recurrent, or Metastatic Cervical Cancer
Study of Pembrolizumab Plus Chemotherapy versus Chemotherapy Plus Placebo in Patients with Cervical Cancer
Sponsor: MERCK SHARP & DOHME CORP
Enrolling: Female Patients Only
IRB Number: AAAS0820
U.S. Govt. ID: NCT03635567
Contact: Reena Vattakalam: 212-342-6895 / rmv2110@cumc.columbia.edu
Additional Study Information: Test the safety and effectiveness of the research study drug, pembrolizumab (MK-3475) in combination with chemotherapy, compared to chemotherapy plus placebo (a look-alike drug with no active ingredients) in women with persistent, recurrent, or metastatic cervical cancer. To test if adding pembrolizumab (MK-3475) to standard chemotherapy improves survival women with persistent, recurrent, or metastatic cervical cancer. Pembrolizumab (MK-3475), also called KEYTRUDA has been approved for use in certain types of cancers; however it may not be approved to treat your type of cancer.
This study is closed
Investigator
Jason Wright, MD
Do You Qualify?
Have you been diagnosed with cervical cancer? Yes No
Is your cancer not responsive to treatment such as surgery and/or radiation? Yes No
Are you pregnant or breastfeeding? Yes No
Do you have a known history of HIV, Hepatitis B or Hepatitis C? Yes No
Submit
Cancel
You may be eligible for this study

Place Holder



Cancel
For more information, please contact:
Reena Vattakalam
rmv2110@cumc.columbia.edu
212-342-6895
This website uses cookies as well as similar tools and technologies to understand visitors’ experiences. By continuing to use this website, you consent to Columbia University’s usage of cookies and similar technologies, in accordance with the Columbia University Website Cookie Notice.
I AGREE